scholarly journals Huntington’s disease: a forensic risk factor in women

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Elvina May-Yin Chu ◽  
Mari O’Neill ◽  
Debasish Das Purkayastha ◽  
Caroline Knight
2016 ◽  
Vol 87 (Suppl 1) ◽  
pp. A71.2-A71
Author(s):  
Rebekah Turner ◽  
Elvina Chu

Pteridines ◽  
2002 ◽  
Vol 13 (4) ◽  
pp. 121-125 ◽  
Author(s):  
Andreas Laich ◽  
Friedrich Leblhuber ◽  
Bernhard Widner ◽  
Barbara Frick ◽  
Kurt Jellinger ◽  
...  

Abstract Hyperhomocysteinemia is considered to be an independent risk factor for cardiovascular diseases and atherosclerosis. Also patients with dementia, either of Alzheimer's or of vascular type, may present with elevated homocysteine levels. All these disorders are linked with older age and since hyperhomocysteinemia is also frequent in the healthy elderly, we were interested to determine homocysteine concentrations in a younger population of demented patients suffering from Huntington's disease. In 15 patients with Huntington's disease and in a control group of similar age, serum homocysteine concentrations were measured and changes were compared to concentrations of folate and neopterin, the latter being an indicator of immune activation. A subgroup of patients with Huntington's disease presented with elevated homocysteine concentrations compared to healthy controls of similar age. Moderate hyperhomocysteinemia was related to lower folate concentrations and also to higher neopterin levels which indicate increased immune activation. The correlation of homocysteine with neopterin concentrations points to a possible relationship between the development of hyperhomocysteinemia and immune activation in the patient


2018 ◽  
pp. 20-22
Author(s):  
Ranjan Bhattacharyya

Deutrabenazine is indicated in the management of chorea associated with Huntington’s disease and in the treatment of Tardive dyskinesia in adults by US FDA. However, it should be used with a pinch of salt, as it can raise the risk of depression and suicidal thoughts with unusual behavioural abnormalities specially in patients with Huntington’s disease. The family history is an added risk factor and close monitoring is required and the molecule is contraindicated in this group of patients. In hepatic impairment it is also not recommended. It shouldn’t be used with Reserpine. A window period of 3 weeks after discontinuation of reserpine and 2 weeks for MAO inhibitors and tetrabenazine or valbenazine is recommended. Keyword : Deutetrabenazine, VMAT2 inhibitor, Huntington’s disease, Tardive dyskinesia.


2014 ◽  
Vol 85 (Suppl 1) ◽  
pp. A57-A57
Author(s):  
E. Chu ◽  
C. Knight ◽  
M. O'Neill ◽  
D. Das Purkayastha

Sign in / Sign up

Export Citation Format

Share Document